GT Medical Technologies Announces the Presentation of Clinical Data on GammaTile® Therapy in the Treatment of Recurrent Glioblastomas at the 2022 American Association of Neurological Surgeons Scientific Meeting

GT Medical Technologies, Inc. announced today that new data on the company’s innovative GammaTile Therapy for patients with operable brain tumors will be presented via an oral, live presentation at the 2022 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in Philadelphia, PA. The abstract will provide the first report of clinical outcomes for recurrent glioblastoma patients treated with FDA-cleared GammaTile Therapy.

Novocure Announces Clinical Trial Collaboration with GT Medical Technologies

This press release announces a trial collaboration between Novocure and GT Medical Technologies to develop Tumor Treating Fields (TTFields) together with GammaTile Therapy for the treatment of recurrent GBMs. Tumor Treating Fields are electric fields that disrupt cancer cell division. The study will evaluate the effectiveness and safety of adjuvantly using TTFields prior to resection + GammaTile, with progression free survival (PFS) for the ITT population being the primary endpoint.